FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2531661710> ?p ?o ?g. }

• W2531661710 endingPage "79232" @default.
• W2531661710 startingPage "79217" @default.
• W2531661710 abstract "BET bromodomain inhibitors are very promising novel anticancer agents, however, single therapy does not cause tumor regression in mice, suggesting the need for combination therapy. After screening a library of 2697 small molecule compounds, we found that two classes of compounds, the quinone-containing compounds such as nanaomycin and anti-microtubule drugs such as vincristine, exerted the best synergistic anticancer effects with the BET bromodomain inhibitor JQ1 in neuroblastoma cells. Mechanistically, the quinone-containing compound nanaomycin induced neuroblastoma cell death but also activated the Nrf2-antioxidant signaling pathway, and the BET bromodomain proteins BRD3 and BRD4 formed a protein complex with Nrf2. Treatment with JQ1 blocked the recruitment of Nrf2 to the antioxidant responsive elements at Nrf2 target gene promoters, and JQ1 exerted synergistic anticancer effects with nanaomycin by blocking the Nrf2-antioxidant signaling pathway. JQ1 and vincristine synergistically induced neuroblastoma cell cycle arrest at the G2/M phase, aberrant mitotic spindle assembly formation and apoptosis, but showed no effect on cell survival in normal non-malignant cells. Importantly, co-treatment with JQ1 and vincristine synergistically suppressed tumor progression in neuroblastoma-bearing mice. These results strongly suggest that patients treated with BET bromodomain inhibitors in clinical trials should be co-treated with vincristine." @default.
• W2531661710 created "2016-10-21" @default.
• W2531661710 creator A5002814280 @default.
• W2531661710 creator A5009084764 @default.
• W2531661710 creator A5011765291 @default.
• W2531661710 creator A5013270397 @default.
• W2531661710 creator A5014079192 @default.
• W2531661710 creator A5014528965 @default.
• W2531661710 creator A5017098534 @default.
• W2531661710 creator A5025489995 @default.
• W2531661710 creator A5026784302 @default.
• W2531661710 creator A5028852936 @default.
• W2531661710 creator A5029523132 @default.
• W2531661710 creator A5031140584 @default.
• W2531661710 creator A5031528165 @default.
• W2531661710 creator A5036482512 @default.
• W2531661710 creator A5046321083 @default.
• W2531661710 creator A5046827913 @default.
• W2531661710 creator A5049900685 @default.
• W2531661710 creator A5051788465 @default.
• W2531661710 creator A5060679925 @default.
• W2531661710 creator A5072009574 @default.
• W2531661710 creator A5072813429 @default.
• W2531661710 creator A5076755343 @default.
• W2531661710 creator A5078090612 @default.
• W2531661710 creator A5084971557 @default.
• W2531661710 creator A5085362634 @default.
• W2531661710 creator A5085722199 @default.
• W2531661710 creator A5085975175 @default.
• W2531661710 date "2016-10-13" @default.
• W2531661710 modified "2023-10-16" @default.
• W2531661710 title "The BET bromodomain inhibitor exerts the most potent synergistic anticancer effects with quinone-containing compounds and anti-microtubule drugs" @default.
• W2531661710 cites W1595597462 @default.
• W2531661710 cites W1915617459 @default.
• W2531661710 cites W1939365747 @default.
• W2531661710 cites W1951627305 @default.
• W2531661710 cites W1965254413 @default.
• W2531661710 cites W1976033223 @default.
• W2531661710 cites W1980022601 @default.
• W2531661710 cites W1980763900 @default.
• W2531661710 cites W1993186884 @default.
• W2531661710 cites W1999142756 @default.
• W2531661710 cites W2001555590 @default.
• W2531661710 cites W2007655798 @default.
• W2531661710 cites W2009949436 @default.
• W2531661710 cites W2024280594 @default.
• W2531661710 cites W2035129407 @default.
• W2531661710 cites W2041535798 @default.
• W2531661710 cites W2057319734 @default.
• W2531661710 cites W2067606868 @default.
• W2531661710 cites W2090714945 @default.
• W2531661710 cites W2090788819 @default.
• W2531661710 cites W2091445911 @default.
• W2531661710 cites W2092258256 @default.
• W2531661710 cites W2095399601 @default.
• W2531661710 cites W2096439168 @default.
• W2531661710 cites W2102118318 @default.
• W2531661710 cites W2109378990 @default.
• W2531661710 cites W2120572492 @default.
• W2531661710 cites W2129129812 @default.
• W2531661710 cites W2130925781 @default.
• W2531661710 cites W2135979413 @default.
• W2531661710 cites W2138625851 @default.
• W2531661710 cites W2140765582 @default.
• W2531661710 cites W2150148604 @default.
• W2531661710 cites W2151614363 @default.
• W2531661710 cites W2160618318 @default.
• W2531661710 cites W2162354443 @default.
• W2531661710 cites W2162696088 @default.
• W2531661710 cites W2164143957 @default.
• W2531661710 cites W2169287961 @default.
• W2531661710 cites W2171262570 @default.
• W2531661710 cites W2263799391 @default.
• W2531661710 cites W2330923897 @default.
• W2531661710 cites W1984573774 @default.
• W2531661710 doi "https://doi.org/10.18632/oncotarget.12640" @default.
• W2531661710 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5346709" @default.
• W2531661710 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27764794" @default.
• W2531661710 hasPublicationYear "2016" @default.
• W2531661710 type Work @default.
• W2531661710 sameAs 2531661710 @default.
• W2531661710 citedByCount "16" @default.
• W2531661710 countsByYear W25316617102017 @default.
• W2531661710 countsByYear W25316617102018 @default.
• W2531661710 countsByYear W25316617102019 @default.
• W2531661710 countsByYear W25316617102020 @default.
• W2531661710 countsByYear W25316617102021 @default.
• W2531661710 countsByYear W25316617102022 @default.
• W2531661710 countsByYear W25316617102023 @default.
• W2531661710 crossrefType "journal-article" @default.
• W2531661710 hasAuthorship W2531661710A5002814280 @default.
• W2531661710 hasAuthorship W2531661710A5009084764 @default.
• W2531661710 hasAuthorship W2531661710A5011765291 @default.
• W2531661710 hasAuthorship W2531661710A5013270397 @default.
• W2531661710 hasAuthorship W2531661710A5014079192 @default.
• W2531661710 hasAuthorship W2531661710A5014528965 @default.
• W2531661710 hasAuthorship W2531661710A5017098534 @default.
• W2531661710 hasAuthorship W2531661710A5025489995 @default.

• next